Mouse Models of Heterologous Flavivirus Immunity: A Role for Cross-Reactive T Cells
Overview
Affiliations
Most of the world is at risk of being infected with a flavivirus such as dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, tick-borne encephalitis virus, and Zika virus, significantly impacting millions of lives. Importantly, many of these genetically similar viruses co-circulate within the same geographic regions, making it likely for individuals living in areas of high flavivirus endemicity to be infected with multiple flaviviruses during their lifetime. Following a flavivirus infection, a robust T cell response is generated and the memory recall of this response has been demonstrated to provide long-lasting immunity, protecting against reinfection with the same pathogen. However, multiple studies have shown that this flavivirus specific T cell response can be cross-reactive and active during heterologous flavivirus infection, leading to the question: It has been proposed that in some cases unfavorable disease outcomes may be caused by lower avidity cross-reactive memory T cells generated during a primary flavivirus infection that preferentially expand during a secondary heterologous infection and function sub optimally against the new pathogen. While in other cases, these cross-reactive cells still have the potential to facilitate cross-protection. In this review, we focus on cross-reactive T cell responses to flaviviruses and the concepts and consequences of T cell cross-reactivity, with particular emphasis linking data generated using murine models to our new understanding of disease outcomes following heterologous flavivirus infection.
Human coronavirus OC43-elicited CD4 T cells protect against SARS-CoV-2 in HLA transgenic mice.
Alves R, Timis J, Miller R, Valentine K, Pinto P, Gonzalez A Nat Commun. 2024; 15(1):787.
PMID: 38278784 PMC: 10817949. DOI: 10.1038/s41467-024-45043-2.
Insights into Zika Virus Pathogenesis and Potential Therapeutic Strategies.
Camacho-Concha N, Santana-Roman M, Sanchez N, Velasco I, Pando-Robles V, Pedraza-Alva G Biomedicines. 2023; 11(12).
PMID: 38137537 PMC: 10741857. DOI: 10.3390/biomedicines11123316.
Jaeger A, Crooks C, Weiler A, Bliss M, Rybarczyk S, Richardson A Sci Adv. 2023; 9(26):eadg3444.
PMID: 37390207 PMC: 10313173. DOI: 10.1126/sciadv.adg3444.
Aggarwal C, Ramasamy V, Garg A, Shukla R, Khanna N Front Immunol. 2023; 14:1128784.
PMID: 36926350 PMC: 10011089. DOI: 10.3389/fimmu.2023.1128784.
West Nile Virus Vaccination Protects against Usutu Virus Disease in Mice.
Salgado R, Hawks S, Frere F, Vazquez A, Huang C, Duggal N Viruses. 2021; 13(12).
PMID: 34960621 PMC: 8704473. DOI: 10.3390/v13122352.